Area Development
CMC Biologics, Inc., a global leader in commercial manufacturing of therapeutic proteins, opened its first-in-class Bioreactor 6Pack manufacturing facility at its campus in Bothell, Washington.

"From the beginning, our ambition has always been to be leaders in our field – using the best technology, having the best process development capabilities and supplying API for marketed drug product," David Kauffmann, Chairman of the Board of CMC Biologics and Managing Director of European Equity Partners said. "This expansion is a testimony that we are living by our ambition and continue to find the best solutions for our clients."

Gustavo Mahler, PhD, Global Chief Operations Officer of CMC Biologics said, "This expansion is fundamental to furthering our goal of delivering commercial manufacturing solutions to our customers and lifesaving medicines to patients around the world."

According to the firm, its Bioreactor 6Pack configuration consists of six 2000L single-use production bioreactors and a 2000L seed train, allowing for flexible production with scales from 2000L to12000L in a single production suite. The bioreactors can be run in single unit operations or in groups, simultaneously, sequentially or in staggered fashion to achieve our customers' desired production needs.

Maura Little, Director of Life Science and Global Health Development of Washington State, said, "I'm delighted to see Washington State's life science sector continue to grow and expand. CMC Biologics has been a tremendous partner to the local biotech community, and the Governor and I appreciate your dedication to our state economy and the life science community. The Washington state life science sector employs more than 42,000 individuals and has become Washington's fifth largest sector, where roughly 1,000 life science organizations call home. The life science industry will provide the people of Washington State with jobs and prosperity into the next century."